Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
IKT
SellHot AirInhibikase Therapeutics, Inc. · Healthcare · United States · $336M · Avg Vol: $1M/d
32
StockRankGet insider-trade alerts
Q
36
V
29
M
58
P/E (TTM)
—
ROE
-52.0%
D/E
0.0x
Dividend %
—
COMPANY DESCRIPTION
Inhibikase Therapeutics, Inc. operates as a clinical-stage pharmaceutical company that develops therapeutics to modify the course of cardiopulmonary diseases, with a primary focus on pulmonary arterial hypertension (PAH), a progressive, life-threatening disease characterized by pulmonary vascular...
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | — | — | 0.2M | 0.3M | — |
| EPS | -0.11 | -0.12 | -0.51 | -0.49 | — | -0.44 | -0.45 | -0.43 | — |
| Shares | 157.0M | 157.0M | 157.0M | 131.7M | -16.1% | 139.5M | — | — | — |
| Debt | 0.4M | 0.2M | 0.1M | 0 | -43.9% | — | — | — | — |
| Equity | 21.0M | 11.0M | 94.9M | 172.9M | 101.8% | — | — | — | — |
| Op CF | -17.4M | -18.1M | -19.1M | -27.8M | — | -42.6M | — | — | — |
| Inv CF | -16.0M | 11.7M | -37.0M | 2.1M | — | — | — | — | — |
| Fin CF | -0.2M | 8.4M | 103.5M | 108.5M | — | — | — | — | — |
Loading 1Y...
PRICE (1Y)+9.0%
SMA 50SMA 200
Close
$2.41
RSI (14)
47.4
52W High
$2.61
From 52W High
0.9%
SCORE BREAKDOWN
Quality
36
ROIC
-32.3%23.2
ROE
-52.0%17.7
GP/Assets
—N/A
Op. Margin
0.0%38.1
FCF/Assets
-15.6%24.5
Piotroski
324.6
Int. Cover
—N/A
D/E Ratio
0.00x98.0
Current Ratio
15.82x93.7
Value
29
P/E (TTM)
—N/A
EV/EBITDA
-4.5x25.0
P/FCF
—N/A
P/B
2.8x48.1
P/S
—N/A
Div Yield
—N/A
Momentum
58
52W High %
92%89.6
RS 6M
10%75.0
SMA 50/200
1.21x88.9
EPS Rev 4W
-4.6%14.1
EPS Rev 12W
—N/A
EPS Improve
+2%23.6
Q Growth
—N/A
FUNDAMENTALS
Market Cap
$336M
P/E (Forward)
-5.8x
Gross Margin
—
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of IKT are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| IKT | Inhibikase Therapeutics, Inc.(you) | $336M | 32 | Sell |
| PALI | Palisade Bio, Inc. | $349M | 33 | Sell |
| ABEO | Abeona Therapeutics Inc. | $339M | 39 | Hold |
| WHWK | Whitehawk Therapeutics, Inc. | $263M | 35 | Hold |
| SABS | SAB Biotherapeutics, Inc. | $345M | 25 | Sell |
| PRLD | Prelude Therapeutics Incorporated | $437M | 29 | Sell |
| ANTX | AN2 Therapeutics, Inc. | $211M | 33 | Sell |
| PRTC.L | PureTech Health plc | $415M | 26 | Sell |
| XFOR | X4 Pharmaceuticals, Inc. | $401M | 25 | Sell |
| NAGE | Niagen Bioscience, Inc. | $260M | 38 | Hold |
Peer medians: ROE -30.5% · P/E 27.0x · Gross margin 58.3%